Abstract
The article deals with the specifics of the modern regulatory architecture of the world pharmaceutical market. The characteristics of the national and supranational levels of regulation of the pharmaceutical market have been characterized, and key players at each level have been identified. It is determined that multilevel representation and diversified activities of regulatory institutions at national and supranational levels in recent decades have formed a "framework" of regulatory architecture of the global pharmaceutical market. It is concluded that optimization of the regulatory parameters of the market in terms of the ratio of protectionist and liberalization instruments and levers is of priority importance for each state.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
